Nautilus Biotechnology, Inc.

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Nautilus Biotechnology Second Quarter 2025 earnings conference call. At this time, all participants are on the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that time, you need to press star 1-1 on your telephone keypad. At this time, I would like to turn the conference over to Ms. Jean-Yong Yi, Investor Relations. Ma'am, please begin.

Earlier today, Nautilus released financial results for the quarter ended June 30, 2025. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujal Patel, co-founder and CEO, Grog Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal security laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on July 30, 2025. With that, I'll turn the call over to Susil.

Thanks, Jian, and thank you all for joining us. Q2 was a milestone quarter for Nautilus. Not only did we continue our momentum across both targeted and broad-scale proteomic development efforts, but we also publicly shared the first preprint to feature novel data generated using the Nautilus. We believe that this -its-kind proteiform data across a range of important biological systems can only be generated on our platform. No other analysis method comes close. The manuscript, now live on Bioarchive, represents nearly a decade of pioneering work by our team and collaborators. In it, we introduce and validate the application of our iterative mapping method, showing that it can measure proteoforms at a resolution and breadth never before possible. The results speak for themselves. Our approach demonstrated unprecedented dynamic range and industry-leading reproducibility. Even more exciting, early biological insights from this work suggests that iterative mapping may illuminate new mechanisms of tau biology, potentially opening the door to a new generation of neurodegenerative disease diagnostics and therapeutics. Parag will elaborate on these results presented in the manuscript shortly. We believe that this manuscript is both scientific validation and a significant external milestone for Nautilus, and that it sets a new bar in the field of proteomics. I want to recognize the Herculean efforts of our team, as well as our partners at Genentech, the Neural Stem Cell Institute, and Mount Sinai Health System. Zooming out, this quarter, we main-focus on building engagement around our tau proteoform assay and laying the foundation for external collaborations. Feedback from researchers is highly enthusiastic. Many now see Nautilus as a forerunner in decoding the complexity of post-translational modifications with the resolution necessary to drive meaningful biological and therapeutic breakthroughs. This enthusiasm is translating into real momentum. We've continued to deepen our conversations with academic, pharma, and non-profit partners, and the ability to now reference our manuscript gives us a new level of credibility and visibility. The discussions we're having today are more strategic, focused not only on tau, but also broader use cases for targeted proteoform analysis across neurology, oncology, and immunology. To provide more detail on our R&D efforts, let me now turn the call over to Parag. Parag?